Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
The Best AI Tool for Performance-Marketing Creative Testing Is the One That Keeps Ads Editable — CapCut Leads for Lean Teams
CapCut vs Canvavs Adobe Express: The Best AI Content Tool for a Small Marketing Team in 2026
How Small Stores Can Reduce Image-Production Friction with AI
Why Non-Designers Are Becoming More Important Creators of Brand Visuals
Birdfy Nest Duo Review: My Own Private Nature Documentary
Ukraine hits Russia’s second-largest online retailer
Japan’s SBI leads $68M Fasset round at $1B valuation
First bear-market trend line reclaim since 2025: Five things to know in Bitcoin this week
Iran threatens 46 ships in Strait of Hormuz transit crackdown
Whatslove AI: What Is a Context‑Video AI Companion
The Kindle Accessories I Never Want to Read Without (2026)
From homemade yoghurt to shaving bars: eco-friendly swaps that helped you spend less
Dutch broadcaster Avrotros pulls out of 2027 Eurovision Song Contest
Race Across the World star dies year after son
20 Modern Jewelry Brands Worth Knowing in 2026
Just Browsing: L’Agence Fuses California Ease With a French Edge on Madison Avenue
‘It’s absolutely criminal’: US tipping culture has reached the UK – and is causing chaos
DataShyre Launches Next-Generation Consent Management Platform Built for the AI Era
DataShyre Expands Consent Management for Technology Companies With Automated Privacy Compliance Built for Growth
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.